Special Issue "Animal Endocrinology and Medicine Research"
A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Veterinary Clinical Studies".
Deadline for manuscript submissions: 30 November 2021.
Special Issue Editor
Interests: insulin dysregulation; adrenocorticotropic hormone; metabolism; endocrinology; hormonal disorders; laminitis; inflammation; obesity; equine; diagnosis
Special Issue Information
Dear Colleagues,
I am excited to invite you to contribute to this special issue on Animal Endocrinology that I have the honour of editing for Animal.
Endocrinology has become a dominant field in veterinary medicine with the documentation of new disorders in many domestic and wildlife species. Disorders initially described in human medicine have now been documented in many animals with both similarities and specificities. Comparative endocrinology has benefited both animals and humans as it has allowed a better understanding of hormonal diseases and their pathophysiology.
This Special Issue will take a One-Medicine approach to endocrinology focusing on animal studies unravelling pathophysiology of endocrine disorders, improving their diagnosis and enhancing their management in all animal species.
Dr. Francois-Rene Bertin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endocrinology
- insulin
- endocrine pancreas
- diabetes
- thyroid
- parathyroid
- hypothalamo-pituitary adrenal axis
- sex hormones
- obesity
- metabolism
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1. Anti-obesity and hyperglycemic effect of mirtazapine by decreasing adipocyte hypertrophy and increasing glucose transporter expression in obese mice
Abstract: Metabolic syndrome is involved in the development of diabetes and cardiac, cerebrovascular, and kidney diseases. Mirtazapine is clinically used as an atypical second-generation antipsychotic drug with less severe side effects than atypical first-generation antipsychotics; however, reports have indicated that mirtazapine may affect blood glucose levels and obesity. Therefore, we investigated the antiobesity effects of mirtazapine in male C57BL/6J mice on a high-fat diet (HFD). Mice treated with mirtazapine (10 mg/kg per day for 4 weeks) exhibited reduced body weight, liver and epididymal fat pads, daily food efficiency, insulin levels, serum triglyceride levels, aspartate aminotransferase (AST) levels, and fatty acid regulation marker expression (fatty acid synthase) compared with HFD control mice. Dissection of mirtazapine-treated mice revealed a marked reduction in average fat cell size of epididymal white adipose tissue fatty and liver scores, paralleling the activation of AMP-activated protein kinase (AMPK) expression. These results indicated that mirtazapine prevented the effect of the HFD on the rate of accretion in body weight by reducing lipid accumulation. Notably, glucose tolerance and blood glucose levels in mirtazapine-treated animals with higher GLUT4 expression were lower than those in HFD-fed mice. Mirtazapine may serve as a body weight control strategy and antihyperglycemic therapy.
Keywords: adipocyte; blood glucose; insulin; mirtazapine; obesity